文献速递MDS 与骨髓增殖性肿瘤

抑制ERK1/2信号通过降低骨桥蛋白血浆水平预防骨髓纤维化小鼠模型中的骨髓纤维化

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model.
PubMed 文献 · Leukemia · 2023-03-16

该研究在体外筛选骨桥蛋白(OPN)表达抑制剂,鉴定出ERK1/2是OPN产生的主要调控因子。在罗米司亭诱导的骨髓纤维化(MF)小鼠模型中,OPN血浆水平升高与骨髓纤维化发展相关,抑制ERK1/2可显著减少OPN产生和骨髓纤维化,且该抗纤维化效应主要通过减少OPN产生实现。

要点

  • ERK1/2是骨桥蛋白(OPN)产生的主要调控因子。
  • 罗米司亭诱导的MF小鼠模型中,OPN血浆水平升高与骨髓纤维化发展相关。
  • 抑制ERK1/2可减少OPN产生和骨髓纤维化,抗OPN中和抗体可重现该效应。

核心结论

  • OPN是MF中新的可成药靶点,为基于抑制ERK1/2驱动的OPN产生或中和OPN活性的抗纤维化治疗开辟了道路。

研究设计与样本

  • 研究采用体外筛选OPN表达抑制剂,并在罗米司亭诱导的MF小鼠模型中进行体内验证。

主要发现

  • 体外筛选鉴定出ERK1/2是OPN产生的主要调控因子。
  • 罗米司亭诱导的MF小鼠模型中,OPN血浆水平升高与骨髓纤维化发展相关。
  • 抑制ERK1/2导致罗米司亭处理小鼠的OPN产生和骨髓纤维化显著减少。
  • ERK1/2抑制的抗纤维化效应主要通过减少OPN产生实现,因为给予抗OPN中和抗体可重现该效应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clonal myeloproliferation and development of bone marrow (BM) fibrosis are the major pathogenetic events in myelofibrosis (MF). The identification of novel antifibrotic strategies is of utmost importance since the effectiveness of current therapies in reverting BM fibrosis is debated. We previously demonstrated that osteopontin (OPN) has a profibrotic role in MF by promoting mesenchymal stromal cells proliferation and collagen production. Moreover, increased plasma OPN correlated with higher BM fibrosis grade and inferior overall survival in MF patients. To understand whether OPN is a druggable target in MF, we assessed putative inhibitors of OPN expression in vitro and identified ERK1/2 as a major regulator of OPN production. Increased OPN plasma levels were associated with BM fibrosis development in the Romiplostim-induced MF mouse model. Moreover, ERK1/2 inhibition led to a remarkable reduction of OPN production and BM fibrosis in Romiplostim-treated mice. Strikingly, the antifibrotic effect of ERK1/2 inhibition can be mainly ascribed to the reduced OPN production since it could be recapitulated through the administration of anti-OPN neutralizing antibody. Our results demonstrate that OPN is a novel druggable target in MF and pave the way to antifibrotic therapies based on the inhibition of ERK1/2-driven OPN production or the neutralization of OPN activity.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bianchi E, Rontauroli S, Tavernari L, et al. Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model. Leukemia. 2023. PMID: 36928007. doi:10.1038/s41375-023-01867-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。